CLINICAL TRIALS PROFILE FOR ATORVASTATIN CALCIUM; EZETIMIBE

All Clinical Trials for atorvastatin calcium; ezetimibe

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02460159 ↗	A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2015-06-23	This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Atorvastatin up to 20 mg. There is no formal hypothesis for the study.
NCT02461004 ↗	CKD-391 Pharmacokinetic Study	Completed	Chong Kun Dang Pharmaceutical	Phase 1	2015-07-01	A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
NCT02501200 ↗	CKD-391 Pharmacokinetic Study Phase I	Completed	Chong Kun Dang Pharmaceutical	Phase 1	2015-08-01	A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
NCT05920889 ↗	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	COMPLETED	Linyi People's Hospital	PHASE2	2023-08-01	Endovascular thrombectomy (EVT) is a highly effective therapy for acute ischemic stroke with large vessel occlusion (LVO). EVT was proven efficacious in selected patients with symptoms onset or last-known-well time of up to 24 hours. With a number-needed-to-treat (NNT) of 2.3-2.8 to achieve functional independence, EVT had become the current state-of-the-art treatment for ischemic stroke with LVO. Nevertheless, more than half of LVO strokes suffered from functional dependence or death despite EVT. Futile EVTs were contributed by peri-procedural malignant brain edema (MBE) and symptomatic intracranial hemorrhage (sICH). Studies suggested that 26.9% of EVTs were complicated by MBE, whereas sICH was present in 6-9% of LVO patients who received EVT. The fundamental pathophysiology of MBE and sICH is blood-brain-barrier (BBB) disruption secondary to ischemia, mechanical and reperfusion injury. These pathological processes can result in increased tissue permeability, excess production of oxygen free radicals and inflammatory response that eventually lead to hemorrhage and edema. Poor collateral circulation, proximal LVOs, intravenous thrombolysis, blood pressure and glucose fluctuation had all been implicated to in MBE and sICH. However, these risk factors were either unmodifiable or not shown to improve EVT outcomes. The preliminary results of a recent randomized trial even suggested harmful effects of intensive blood pressure following EVT. With indications of EVT are expanding to patients with prolonged ischemia and large ischemic cores, enhancing BBB and neuronal tolerance to ischemia and reperfusion therapies may hugely impact on EVT outcomes. Recent animal models have shown that glucagon-like peptide peptide-1 receptor agonists (GLP-1RA) significantly reduced infarct volume and neurological deficits following temporary or permanent middle cerebral artery occlusion. These effects were likely due to the anti-oxidant, anti-inflammatory and anti-apoptotic properties of GLP-1RA that protected BBB integrity and ischemic neurons during induced LVO and/or reperfusion. Investigator hypothesizes that compared to standard reperfusion strategies, administration of GLP-1RA in LVO patients who receive EVT may prevent the development of MBE and sICH, and improve neurological outcomes. In this randomized, open-label pilot study, investigator aims to determine the effect of semaglutide, a GLP-1RA, on the radiological and clinical outcomes in LVO patients undergoing EVT.
NCT05920889 ↗	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	COMPLETED	Chinese University of Hong Kong	PHASE2	2023-08-01	Endovascular thrombectomy (EVT) is a highly effective therapy for acute ischemic stroke with large vessel occlusion (LVO). EVT was proven efficacious in selected patients with symptoms onset or last-known-well time of up to 24 hours. With a number-needed-to-treat (NNT) of 2.3-2.8 to achieve functional independence, EVT had become the current state-of-the-art treatment for ischemic stroke with LVO. Nevertheless, more than half of LVO strokes suffered from functional dependence or death despite EVT. Futile EVTs were contributed by peri-procedural malignant brain edema (MBE) and symptomatic intracranial hemorrhage (sICH). Studies suggested that 26.9% of EVTs were complicated by MBE, whereas sICH was present in 6-9% of LVO patients who received EVT. The fundamental pathophysiology of MBE and sICH is blood-brain-barrier (BBB) disruption secondary to ischemia, mechanical and reperfusion injury. These pathological processes can result in increased tissue permeability, excess production of oxygen free radicals and inflammatory response that eventually lead to hemorrhage and edema. Poor collateral circulation, proximal LVOs, intravenous thrombolysis, blood pressure and glucose fluctuation had all been implicated to in MBE and sICH. However, these risk factors were either unmodifiable or not shown to improve EVT outcomes. The preliminary results of a recent randomized trial even suggested harmful effects of intensive blood pressure following EVT. With indications of EVT are expanding to patients with prolonged ischemia and large ischemic cores, enhancing BBB and neuronal tolerance to ischemia and reperfusion therapies may hugely impact on EVT outcomes. Recent animal models have shown that glucagon-like peptide peptide-1 receptor agonists (GLP-1RA) significantly reduced infarct volume and neurological deficits following temporary or permanent middle cerebral artery occlusion. These effects were likely due to the anti-oxidant, anti-inflammatory and anti-apoptotic properties of GLP-1RA that protected BBB integrity and ischemic neurons during induced LVO and/or reperfusion. Investigator hypothesizes that compared to standard reperfusion strategies, administration of GLP-1RA in LVO patients who receive EVT may prevent the development of MBE and sICH, and improve neurological outcomes. In this randomized, open-label pilot study, investigator aims to determine the effect of semaglutide, a GLP-1RA, on the radiological and clinical outcomes in LVO patients undergoing EVT.

Clinical Trial Conditions for atorvastatin calcium; ezetimibe

Condition Name

Condition Name for atorvastatin calcium; ezetimibe
Intervention	Trials
Healthy	2
Brain Diseases	1
Heterozygous Familial Hypercholesterolemia	1
Hypercholesterolemia	1

Condition MeSH

Condition MeSH for atorvastatin calcium; ezetimibe
Intervention	Trials
Hypercholesterolemia	1
Stroke	1
Ischemic Stroke	1
Brain Diseases	1

Clinical Trial Locations for atorvastatin calcium; ezetimibe

Trials by Country

Trials by Country for atorvastatin calcium; ezetimibe
Location	Trials
Korea, Republic of	1
China	1
Hong Kong	1

Clinical Trial Progress for atorvastatin calcium; ezetimibe

Clinical Trial Phase

Clinical Trial Phase for atorvastatin calcium; ezetimibe
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for atorvastatin calcium; ezetimibe
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for atorvastatin calcium; ezetimibe

Sponsor Name

Sponsor Name for atorvastatin calcium; ezetimibe
Sponsor	Trials
Chong Kun Dang Pharmaceutical	2
Merck Sharp & Dohme Corp.	1
Linyi People's Hospital	1

Sponsor Type

Sponsor Type for atorvastatin calcium; ezetimibe
Sponsor	Trials
Industry	3
OTHER	2

Clinical Trials Update, Market Analysis, and Projection: Atorvastatin Calcium + Ezetimibe

Last updated: May 4, 2026

Atorvastatin calcium plus ezetimibe is the branded combination therapy that targets LDL-C reduction via complementary mechanisms: atorvastatin inhibits HMG-CoA reductase and ezetimibe blocks intestinal cholesterol absorption. The combination remains a core option in hyperlipidemia and mixed dyslipidemia after inadequate response to statins or when greater LDL-C lowering is needed. Commercial momentum tracks guideline adoption, formulary status, and generic penetration of both components. Near-to-midterm growth depends more on share gains and access (including higher-intensity statin regimens and fixed-dose convenience) than on molecule-level innovation.

What is the approved product landscape and where does the combo sit?

Which fixed-dose combinations define the commercial market?

The clinical and commercial discussion centers on fixed-dose combinations of atorvastatin and ezetimibe in multiple strengths. In the US, the core branded reference product is:

• Liptruzet (atorvastatin calcium/ezetimibe), fixed dose tablets.

Other market participants exist through generic fixed-dose availability of the same active ingredients and strengths (market value depends on pricing and payer coverage, not new clinical differentiation).

How is the combination positioned in treatment algorithms?

Clinicians use atorvastatin/ezetimibe to achieve LDL-C goals in adults with:

• Primary hyperlipidemia and mixed dyslipidemia
• Homozygous familial hypercholesterolemia (HoFH) (as adjunct to other lipid-lowering therapies)
• Patients not at goal on statin therapy alone

Its role is typically earlier than PCSK9 inhibitors in stepped-care pathways, but later than maximally tolerated statins when additional LDL-C reduction is required.

What clinical evidence and recent trials matter for the next 12 to 36 months?

Which outcomes trials anchor efficacy and safety?

The combination’s clinical credibility is supported by large LDL-C lowering and cardiovascular outcomes evidence and robust safety experience from both components. Key anchor points include:

• IMPROVE-IT: simvastatin/ezetimibe showed cardiovascular benefit versus simvastatin alone in post-acute coronary syndrome patients; this established ezetimibe’s role on top of statin therapy for event reduction in a guideline setting. (Source: IMPROVE-IT publication in NEJM; [1])
• LDL-C lowering magnitude and predictable safety profile for statin plus ezetimibe are consistent with mechanism and confirmatory clinical pharmacology.

What does the current trial pipeline look like (by trial type)?

A “clinical trials update” for this specific fixed combination typically trends toward:

1. Real-world evidence (claims database studies, registry analyses): adherence, persistence, and LDL-C attainment after switching to fixed-dose therapy.
2. Comparative effectiveness studies: fixed-dose adherence vs separate dosing, and effectiveness vs alternative add-ons (e.g., bile acid sequestrants) in routine care.
3. Formulation and bioequivalence work for generics and strength expansion: these often show up as regulatory studies rather than large efficacy outcomes trials.
4. Special populations: hepatic or renal impairment, elderly, and adherence in high-risk subgroups.

Because atorvastatin and ezetimibe are established actives, the dominant incremental science is access and utilization rather than new endpoint biology.

What is the practical read-through for 2025 to 2028?

• The expected clinical impact of new studies is mainly incremental: tighter evidence on adherence and lipid goal attainment in real-world practice, plus post-marketing safety surveillance.
• No new mechanism-of-action for this combo is imminent; growth hinges on how patients and payers use it inside lipid management pathways.

What is the market size, competitive structure, and pricing power?

How big is the opportunity and what drives demand?

The addressable market is the chronic lipid-lowering population requiring LDL-C lowering beyond lifestyle, including:

• Primary hyperlipidemia
• Mixed dyslipidemia
• High and very-high cardiovascular risk patients not at LDL-C goals on statins alone

Demand drivers:

• Guideline persistence for LDL-C targets
• Uptake of high-intensity or maximally tolerated statin regimens, with add-on therapy when goals are not met
• Formulary placement and step edits (prior authorization frequency changes the effective patient access window)
• Generic share shift for atorvastatin and ezetimibe components and any fixed-dose generics

Who competes with atorvastatin/ezetimibe?

Competition spans both same-class and next-class add-on options:

• Statin monotherapy (including generic atorvastatin): competes on price and inertia.
• Ezetimibe monotherapy: competes when clinicians choose separate add-on dosing.
• PCSK9 inhibitors (evolocumab, alirocumab): compete at higher LDL-C reduction and in patients with very high risk where payer criteria are met.
• Bempedoic acid (for selected indications): competes in statin-intolerant cohorts.
• Inclisiran (PCSK9 siRNA) and other lipid agents: competes on dosing convenience and payer contracting.
• Bile acid sequestrants: competes in constrained populations and pregnancy planning.

Within this landscape, atorvastatin/ezetimibe’s primary economic advantage is lower cost versus PCSK9-class therapies, with stronger LDL-C reduction than statin alone.

What pricing and margin pattern should be expected?

• Fixed-dose combos face generic pressure as ezetimibe and atorvastatin are off-patent actives in most markets.
• Margin is shaped more by:
  • Net price after rebates and formulary contracts
  • Channel mix (commercial vs Medicare vs Medicaid)
  • Utilization controls (PA criteria and step therapy)

This profile typically results in a mature product market: volume stability with periodic price compression and share shifts based on formulary mechanics.

What market share and adoption trajectory is most likely?

What is the likely adoption pattern of the fixed-dose combo?

Adoption usually follows a predictable curve:

• Initial years show adoption through clinician familiarity and fixed-dose convenience.
• Over time, share stabilizes as generics enter and payers tighten criteria for alternatives like PCSK9 inhibitors.
• Growth, when it occurs, comes from:
  • Consolidation of dosing regimens (single pill advantage)
  • Improved adherence in patient populations with suboptimal statin adherence
  • Higher-intensity statin titration followed by ezetimibe add-on to reach LDL-C targets

Where does the combo fit against PCSK9 inhibitors and inclisiran?

• For many payer systems, atorvastatin/ezetimibe is a step therapy gate.
• PCSK9 inhibitors are typically reserved for:
  • Documented very high risk
  • LDL-C not at goal on maximally tolerated statin plus ezetimibe
  • Familial hypercholesterolemia criteria in some systems

Inclisiran also often requires evidence of inadequate response to oral therapies.

What projections support investment or R&D planning?

How should the next 3 to 5 years be modeled?

Model the market with three layers:

1. Baseline therapy growth: expansion of treatable populations and guideline adherence
2. Share migration:
   • Switch from statin monotherapy to fixed-dose combo when goals are not met
   • Switch between branded and generic fixed-dose formulations
3. Price realization:
   • Net price erosion driven by generic penetration and contracting dynamics
   • Rebate intensity and payer formulary tier

A credible forecast framework is:

• Volume: modest growth to flat-to-slightly down depending on payer tightening and generic share.
• Value: flattish to declining as price compresses and generic mix increases.
• Net effect: total category stays large but upside comes from adherence-led incremental prescribing and fixed-dose convenience retention.

Scenario range (directional)

Given the mature nature of both actives and the fixed-dose convenience advantage, a practical range for 2025 to 2028 is:

• Base case: volume stable-to-low growth; value slight contraction from net price erosion.
• Upside case: stronger fixed-dose switching and adherence offsets price declines.
• Downside case: tighter payer step edits and accelerated generic substitution reduce value and volume.

These scenarios should be applied to region-specific contracting, because payer policies differ materially between the US, Europe, and emerging markets.

What R&D and clinical strategy implications follow from the evidence and market realities?

What should drug developers and partners prioritize?

For established combinations with generic competition, differentiation is limited at the molecule level. The highest ROI focuses on:

• Evidence for adherence and goal attainment: real-world and pragmatic designs
• Formulary and payer evidence packages: health economics, persistence, and resource utilization
• Special population protocols: hepatic/renal impairment, older adults, and statin intolerance management workflows
• Strength-optimized fixed-dose regimens: matching dose titration paths to clinical LDL-C goals

What endpoints are most likely to move reimbursement decisions?

• LDL-C goal attainment rates at clinically relevant time points
• Adherence and persistence metrics
• Avoidance of treatment escalation to PCSK9 inhibitors (in systems using step therapy)
• Safety signals in routine care, including liver enzymes and muscle-related events

Key Takeaways

• Atorvastatin/ezetimibe remains a central add-on option in LDL-C lowering due to complementary mechanisms and established cardiovascular outcome relevance in the ezetimibe-on-statin evidence base (including IMPROVE-IT for the ezetimibe class).
• The clinical “update” for this combination is largely pragmatic: real-world adherence, persistence, and lipid goal attainment, plus formulation and bioequivalence work driven by generic expansion.
• The market is mature with competitive pressure from statin monotherapy, ezetimibe monotherapy, and higher-potency injectables (PCSK9 inhibitors and inclisiran) that are typically accessed after step therapy.
• Near-term growth is more likely to come from fixed-dose switching and payer access mechanics than from new clinical breakthroughs, while value growth is capped by price compression from generics.

FAQs

1) Does this combo have cardiovascular outcomes evidence?

Yes. Ezitimibe added to statin therapy demonstrated cardiovascular benefit versus statin alone in post-ACS patients in IMPROVE-IT, supporting ezetimibe’s add-on role in guideline-directed LDL-C lowering. [1]

2) What is the main commercial headwind?

Generic penetration and payer contracting reduce net price, particularly as fixed-dose equivalents increase.

3) What is the main reason clinicians use the combo instead of statin alone?

It provides additional LDL-C lowering when patients do not reach LDL-C targets on statin monotherapy.

4) Where do PCSK9 inhibitors and inclisiran fit competitively?

They offer larger LDL-C reductions and dosing convenience, but payer criteria often require failure or inadequate response to maximally tolerated oral therapy including statin plus ezetimibe.

5) What type of clinical work is most likely to appear next?

Real-world effectiveness and adherence studies, comparative studies of fixed-dose vs separate dosing, and regulatory work tied to generic or strength formulations.

---

References

[1] Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J., Theroux, P., ... Braunwald, E. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine, 372(25), 2387-2397. https://doi.org/10.1056/NEJMoa1410489